PhRMA And Trump: 'Go Boldly,' Or Tread Carefully?
Executive Summary
Brand name industry’s image campaign promises to 'Go Boldly' – but there has been nothing bold about its public response to the Trump Administration’s efforts to repeal the Affordable Care Act, the President’s strong words on drug pricing, or even proposed cuts to NIH funding and FDA. Treading carefully makes a lot of sense – but is there a line that PhRMA won’t let the Administration cross?
You may also be interested in...
The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure
The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.
Pharma And Health Reform: Staying On The Sidelines Works Out
The failure of the GOP effort to repeal the Affordable Care Act came after a lot of health care stakeholders warned that proposals in the Senate would lead to a disaster. The pharmaceutical industry maintained its silence on the bill – and probably ends up as one of the winners as the dust settles.
Marathon's Bad News May Help Industry In Pricing Debate
Wall Street Journal brings Marathon Pharmaceuticals back to the front pages – but this time to report that the company is expected to shut down after a 'drug-price revolt.' The rest of the industry should hope the headline catches the President’s eye.